据招股书，2023年-2024年，京新药业实现收入分别为40亿元、41.59亿元；年内溢利分别为6.23亿元、 7.19亿元。 2025年前10个月，公司实现收入为33.44亿元，同比减少2.74%；期内溢利为6.29亿元，同比增长 12.69%。 | | 截至12月31日止年度 | | 截至10月31日止十個月 | | | --- | --- | --- | --- | --- | | | 2023年 | 2024年 | 2024 年 | 2025年 | | | | | (未經審核) | | | | | (人民幣千元) | | | | 收入 | 3.998.835 | 4.158.551 | 3.438.388 | 3.344.144 | | 銷售成本 | (2,032,050) | (2,143,031) | (1,757,318) | (1,730,246) | | 毛利 | 1.966.785 | 2.015.520 | 1.681.070 | 1.613.898 | | 其他收入 | 118.741 | 184.443 | 143,423 | 89.798 | | 预期信貸虧損模式項下的 | | | ...

瑞财经 吴文婷2月25日，浙江京新药业股份有限公司（以下简称"京新药业"）在港交所递交招股书，中信证券为其独家保荐人。 京新药业是一家以创新为驱动力的制药集团，策略重点专注于两大核心疾病领域：中枢神经系统疾病；及心血管及脑血管疾病。 公司的商业模式将已上市产品的商业化与产品管线的持续推进相结合。当前产品组合涵盖药物(包括彷制药、创新药物、中药及生物制剂)；原料药；及医疗 设备。在这个既有的产品组合基础上，公司继续推进在研创新药物的研发。 据招股书，2023年-2024年，京新药业实现收入分别为40亿元、41.59亿元；年内溢利分别为6.23亿元、7.19亿元。 2025年前10个月，公司实现收入为33.44亿元，同比减少2.74%；期内溢利为6.29亿元，同比增长12.69%。 | | 截至12月31日止年度 | | 截至10月31日止十個月 | | | --- | --- | --- | --- | --- | | | 2023年 | 2024年 | 2024年 | 2025年 | | | | | (未經審核) | | | | | (人民幣千元) | | | | 收入 | 3.998.835 | 4.158 ...

截至2026年2月25日收盘，联影医疗（688271）报收于127.45元，较前一交易日上涨0.29%，最新总市值 为1050.39亿元。该股当日开盘127.08元，最高128.55元，最低126.32元，成交额达4.88亿元，换手率为 0.46%。 《联影医疗2025年度业绩快报公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，上海联影医疗科技股份有限公司发布2025年度业绩快报，营业总收入1,382,064.02万元，同比增 长34.18%；归属于母公司所有者的净利润188,779.84万元，同比增长49.60%。扣除非经常性损益的净利 润同比增长77.01%。总资产3,280,039.60万元，同比增长17.00%；归属于母公司的所有者权益 2,159,024.54万元，同比增长8.48%。业绩增长主要受益于创新产品推出、高端产品市场认可度提升、国 内外市场拓展及国内医疗设备更新政策落地。 最新公告列表 ...

智通财经APP获悉，招商证券发布研报称，考虑到数据中心及服务器市场需求高景气、莱尼盈利能力好 于预期，该行预计汇聚科技(01729)2025/26/27年总营收为112/161/209亿港元，净利润7.40/12.50/17.50亿 港元，对应PE为47.3/28.0/20.0倍。维持"强烈推荐"评级。 招商证券主要观点如下： 事件 汇聚科技于2026年2月20日发布完成根据一般授权配售新股份公告，合共108,000,000股配售股份，已成 功配售予不少于六名承配人，配售价为每股15.22港元，配售事项所得款项净额约为1,634.5百万港元。 公司完成配售1.08亿股，净筹约16.35亿元。 公司于2026年2月20日完成配售，共1.08亿股配售股份，占配售完成后已发行股本约5.16%，配售价每股 15.22港元，配售事项所得款项净额约16.35亿港元。公司拟将配售事项所得款项净额总额用于以下用 途：1）约50%用于支持本集团的战略投资及收购；2）约30%用于本集团发展全球业务及扩展海外业 务；3）约20%用于营运资金及一般企业用途，以支持本集团的业务营运及增长。 双轨增长战略，内生+外延持续巩固发展 公司是 ...

该行指出，汇聚科技是立讯体系的重要组成，数通业务绝佳卡位MPO光通信、AI服务器等赛道，有望 实现高质量成长，汽车业务受益于莱尼电缆业务的成功收购，有望快速跃升至全球头部汽车线缆供应 商，医疗设备业务长坡厚雪，积极布局前沿赛道，结合立讯体系赋能协同成长，中长线成长空间可期。 消息面上，汇聚科技宣布，完成配售1.08亿股配售股份，净筹约16.35亿港元。招商证券发布研报称，配 售带来的增量资金将为公司注入强劲发展动能，有利于公司持续拓展MPO、汽车、医疗等核心板块拓 展，在海内外产能扩充及新客户拓展、产业链上下游配套、技术迭代及前沿领域投资布局等方面提供坚 实资金保障，助力公司加速扩张。 汇聚科技(01729)涨超10%，高见19.75港元，再创历史新高。截至发稿，涨9.81%，报19.7港元，成交额 7.04亿港元。 ...

分组1 - Tactile Systems Technology (TCMD) reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.44 per share, and showing an increase from $0.40 per share a year ago, representing an earnings surprise of +3.77% [1] - The company achieved revenues of $103.59 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 10.52%, and up from $85.58 million in the same quarter last year [2] - Tactile Systems Technology has outperformed consensus EPS estimates three times over the last four quarters [2] 分组2 - The stock has underperformed the market, losing about 8.8% since the beginning of the year, compared to a decline of 0.1% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $68.67 million, and for the current fiscal year, it is $0.97 on revenues of $345.33 million [7] - The Medical - Instruments industry, to which Tactile Systems Technology belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

据英国金融时报援引未具名知情人士消息，美国医疗设备制造商丹纳赫即将达成一项近100 亿美元的交 易，收购医疗科技公司迈心诺。若不出现最后时刻意外，收购协议最早可能于周二宣布。丹纳赫与迈心 诺均未立即回应媒体置评请求。 ...

Core Insights - The Chinese medical device industry is experiencing steady growth, with a projected scale of approximately 1,355.87 billion yuan in 2024, reflecting a growth rate of 14.5%, which is 7.5 percentage points higher than the global growth rate [1] Industry Overview - The Chinese government has been actively supporting the upgrade of key equipment in the medical sector, leading to an accelerated development of the medical device industry [1] - The medical equipment sector is the largest segment within the industry, expected to reach a scale of 784.34 billion yuan in 2024, accounting for 57.8% of the total industry [1] Competitive Landscape - The quality and performance of medical diagnostic and treatment devices are improving, with a shift towards high value-added areas, indicating strong international competitiveness [1] Future Projections - The Chinese medical device industry is anticipated to surpass 2 trillion yuan by 2027 [1]

Group 1 - On February 12, Jianda Zhixin's stock price fell by 1.37%, with a trading volume of 66.01 million yuan [1] - The financing data for Jianda Zhixin on the same day showed a financing purchase amount of 5.46 million yuan and a financing repayment of 10.02 million yuan, resulting in a net financing buy of -4.56 million yuan [1] - As of February 12, the total balance of margin trading for Jianda Zhixin was 92.45 million yuan, accounting for 6.39% of its circulating market value [1] Group 2 - As of December 31, Jianda Zhixin had 25,900 shareholders, a decrease of 10.35% from the previous period, while the average circulating shares per person increased by 11.55% to 1,949 shares [2] - For the period from January to September 2025, Jianda Zhixin reported an operating income of 14.861 billion yuan, representing a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million yuan, which is a 45.01% increase year-on-year [2]

Core Insights - Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on innovation-driven pharmaceutical development, targeting two core disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases [1] - Jingxin Pharmaceutical's business model combines the commercialization of existing products with the ongoing development of its product pipeline [1] Company Overview - Jingxin Pharmaceutical (002020.SZ) offers a diverse product portfolio that includes drugs (both generic and innovative), traditional Chinese medicine, biological agents, active pharmaceutical ingredients, and medical devices [1]